Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting CEBPA to restore cellular identity and tissue homeostasis in pulmonary fibrosis
Qi Tan, Jack H. Wellmerling, Shengren Song, Sara R. Dresler, Jeffrey A. Meridew, Kyoung M. Choi, Yong Li, Y.S. Prakash, Daniel J. Tschumperlin
Qi Tan, Jack H. Wellmerling, Shengren Song, Sara R. Dresler, Jeffrey A. Meridew, Kyoung M. Choi, Yong Li, Y.S. Prakash, Daniel J. Tschumperlin
View: Text | PDF
Research Article Pulmonology Stem cells

Targeting CEBPA to restore cellular identity and tissue homeostasis in pulmonary fibrosis

  • Text
  • PDF
Abstract

Fibrosis in the lung is thought to be driven by epithelial cell dysfunction and aberrant cell-cell interactions. Unveiling the molecular mechanisms of cellular plasticity and cell-cell interactions is imperative to elucidating lung regenerative capacity and aberrant repair in pulmonary fibrosis. By mining publicly available RNA-Seq data sets, we identified loss of CCAAT enhancer-binding protein alpha (CEBPA) as a candidate contributor to idiopathic pulmonary fibrosis (IPF). We used conditional KO mice, scRNA-Seq, lung organoids, small-molecule inhibition, and potentially novel gene manipulation methods to investigate the role of CEBPA in lung fibrosis and repair. Long-term (6 months or more) of Cebpa loss in AT2 cells caused spontaneous fibrosis and increased susceptibility to bleomycin-induced fibrosis. Cebpa knockout (KO) in these mice significantly decreased AT2 cell numbers in the lung and reduced expression of surfactant homeostasis genes, while increasing inflammatory cell recruitment as well as upregulating S100a8/a9 in AT2 cells. In vivo treatment with an S100A8/A9 inhibitor alleviated experimental lung fibrosis. Restoring CEBPA expression in lung organoids ex vivo and during experimental lung fibrosis in vivo rescued CEBPA deficiency–mediated phenotypes. Our study establishes a direct mechanistic link between CEBPA repression, impaired AT2 cell identity, disrupted tissue homeostasis, and lung fibrosis.

Authors

Qi Tan, Jack H. Wellmerling, Shengren Song, Sara R. Dresler, Jeffrey A. Meridew, Kyoung M. Choi, Yong Li, Y.S. Prakash, Daniel J. Tschumperlin

×

Figure 6

Rescue of Cebpa expression alleviates lung fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Rescue of Cebpa expression alleviates lung fibrosis.
(A) Schematic timel...
(A) Schematic timeline of AAV9 treatment to alleviate lung fibrosis. (B) Weight of CebpaΔSftpc mice treated with AAV9-mCebpa (n = 6) or AAV9-control (n = 5). (C) qPCR for Cebpa and Sftpc transcripts performed 28 days after bleomycin injury on sorted epithelial cells from CebpaΔSftpc mice lungs treated with AAV9-mCebpa or AAV9-control. (D) Representative H&E staining showing 28 days after bleomycin injury from CebpaΔSftpc mice lung treated with AAV9-dgRNA (n = 3) or AAV9-control (n = 3). (E) Hydroxyproline assay performed 28 days after bleomycin injury from CebpaΔSftpc mice lungs treated with AAV9-mCebpa (n = 6) or AAV9-control (n = 5). (F) qPCR for profibrotic gene transcripts performed 28 days after bleomycin injury from CebpaΔSftpc mice lungs treated with AAV9-mCebpa or AAV9-control. (G) Schematic showing how endogenous Cebpa expression was enhanced using an inactivated CRISPR-Cas9 system. (H) qPCR for Cebpa and Sftpc transcripts in cultured epithelial cells from Cas9 mice and then transfected with the dgRNA1 plasmid (n = 4). (I) Representative Western blot showing Cebpa activation in cultured epithelial cells from Cas9 mice treated with the dgRNA1 plasmid (n = 3). (J) Schematic timeline showing endogenous Cebpa reactivation in the 52- to 60-week-old Cas9 mice with bleomycin induced lung fibrosis. (K) Weight change of Cas9 mice after bleomycin injury and after treatment with AAV9-dgRNA (n = 5) or AAV9-control (n = 5). (L) qPCR of Cebpa and Sftpc transcripts performed 10 days after bleomycin injury on sorted epithelial cells from Cas9 mice treated with AAV9-dgRNA or AAV9-control. (M and N) Representative H&E staining (n = 3) and hydroxyproline assay showing 21 days after bleomycin injury from Cas9 mice lungs treated with AAV9-dgRNA or AAV9-control. (O) qPCR for profibrotic gene transcripts performed 21 days after bleomycin injury from Cas9 mice lungs treated with AAV9-dgRNA (n = 5) or AAV9-control (n = 4). Data were analyzed using a Mann-Whitney U test. *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts